Non-aqueous solutions [Regulatives / Guidelines]

posted by The Outlaw Torn – Europe, 2020-02-24 08:58 (819 d 09:32 ago) – Posting: # 21188
Views: 1,022

Good morning fellow BEBACers,

EMA BE guidelines for aqueous oral solutions are straight forward. I would assume that BE studies cannot be waived for oral solutions formulated with non-aqueous carriers (medium chain triglycerides) due to the potential for formulation effects even when formulations are Q1Q2 (my assumption is that it would not be possible to confirm Q2 due to the heterogeneity of the triglyceride chain lengths obtained from different providers). Is this your understanding as well?

Are there any other issues to consider, either from a regulatory or clinical standpoint, due to the non-aqueous carrier and seeking registration? For example, if the RLD is not available in this pharmaceutical form, would a article 10(3) be more appropriate than 10(1)? Thank you in advance.

Complete thread:

UA Flag
Activity
 Admin contact
22,092 posts in 4,630 threads, 1,567 registered users;
online 10 (1 registered, 9 guests [including 6 identified bots]).
Forum time: Monday 19:31 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5